Merus (NASDAQ:MRUS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.
MRUS has been the topic of several other reports. Zacks Investment Research upgraded shares of Merus from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Friday, March 15th. ValuEngine upgraded shares of Merus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Finally, Citigroup cut their price objective on shares of Merus from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $21.67.
Shares of NASDAQ:MRUS opened at $12.85 on Thursday. The stock has a market capitalization of $292.57 million, a P/E ratio of -3.00 and a beta of -0.12. Merus has a fifty-two week low of $11.00 and a fifty-two week high of $26.74.
A number of institutional investors have recently added to or reduced their stakes in MRUS. Artal Group S.A. acquired a new position in Merus during the 4th quarter valued at about $2,886,000. Laurion Capital Management LP acquired a new position in Merus during the 3rd quarter valued at about $2,104,000. Aquilo Capital Management LLC increased its stake in Merus by 3.6% during the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after buying an additional 44,799 shares during the period. Morgan Stanley increased its stake in Merus by 74.3% during the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after buying an additional 30,538 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Merus by 33.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock valued at $350,000 after buying an additional 4,476 shares during the period. 53.06% of the stock is currently owned by hedge funds and other institutional investors.
Merus Company Profile
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
See Also: Consumer behavior in bull markets
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.